Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1755005
Reference Type
Journal Article
Title
Monte Carlo model for a prototype CT-compatible, anatomically adaptive, shielded intracavitary brachytherapy applicator for the treatment of cervical cancer
Author(s)
Price, MJ; Gifford, KA; Horton, JL, Jr; Eifel, PJ; Gillin, MT; Lawyer, A; Mourtada, F
Year
2009
Is Peer Reviewed?
1
Journal
Medical Physics
ISSN:
0094-2405
Volume
36
Issue
9
Page Numbers
4147-4155
PMID
19810488
DOI
10.1118/1.3193682
Web of Science Id
WOS:000270086000032
Abstract
Purpose: Current, clinically applicable intracavitary
brachytherapy applicators that utilize shielded ovoids contain a pair of tungsten-alloy shields
which serve to reduce dose delivered to the rectum and bladder during source afterloading. After
applicator insertion, these fixed shields are not necessarily positioned to provide optimal
shielding of these critical structures due to variations in patient anatomies. The authors
present a dosimetric evaluation of a novel prototype intracavitary brachytherapy ovoid
[anatomically adaptive applicator (A(3))], featuring a single shield whose position can be
adjusted with two degrees of freedom: Rotation about and translation along the long axis of the
ovoid. Methods: The dosimetry of the device for a HDR (192)Ir was characterized using
radiochromic film measurements for various shield orientations. A MCNPX Monte Carlo model was
developed of the prototype ovoid and integrated with a previously validated model of a v2 mHDR
(192)Ir source (Nucletron Co.). The model was validated for three distinct shield orientations
using film measurements. Results: For the most complex case, 91% of the absolute simulated and
measured dose points agreed within 2% or 2 mm and 96% agreed within 10% or 2 mm. Conclusions:
Validation of the Monte Carlo model facilitates future investigations into any dosimetric
advantages the use of the A(3) may have over the current state of art with respect to
optimization and customization of dose delivery as a function of patient anatomical geometries.
(C) 2009 American Association of Physicists in Medicine. [DOI: 10.1118/1.3193682]
Keywords
brachytherapy; intracavitary applicators; Monte Carlo; adaptive shielding
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity